Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02441062 : Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
PhasePhase 2
AgesMin: 6 Months Max: N/A
Eligibility
Inclusion Criteria:

1. Signed informed consent

2. Age = 6 months

3. Histologically diagnosed neuroendocrine tumor or other tumor with probable
somatostatin receptors subtype 2

4. Karnofsky performance status or Lansky Play Scale status of = 60 (or ECOG/WHO
equivalent)

5. Subject is male; or is a female who is either surgically sterile (has had a documented
bilateral oophorectomy and/or documented hysterectomy), postmenopausal (> 1 years
without menses), =60 years old,or of childbearing potential for whom a pregnancy test
(with the results known prior to investigational product administration) is negative.
A negative pregnancy test will be required for all female subjects with child bearing
potential. If a false pregnancy test is suspected, e.g., perimenopausal condition, an
obstetrician will be consulted to determine if she is/is not capable of becoming
pregnant. Female must also be non-lactating.

Exclusion Criteria:

1. Subject weighs more than 450 pounds. (Subjects who weigh more than 450 pounds will not
be able to fit inside the imaging machines) or otherwise cannot be safely fit into the
imaging system.

2. Inability to lie still for the entire imaging time (due to cough, severe arthritis,
etc.)

3. Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

4. Any additional medical condition, serious intercurrent illness, or other extenuating
circumstance that, in the opinion of the investigator, may significantly interfere
with study compliance.

5. Peptide receptor radionuclide therapy (PRRT) within 4 weeks of Ga-68 DOTATOC PET/CT
scan.

6. Treatment with Sandostatin LAR within 4 weeks, SQ Octreotide within 12 hours, or
Lanreotide injection within 8 weeks of Ga-68 DOTATOC PET/CT (+/-5%).
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02441062      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740